coronavirus

TWiV 918: COVID-19 clinical update #123 with Dr. Daniel Griffin

In COVID-19 clinical update #123, Dr. Griffin discusses rapid diagnostic testing in response to the monkeypox outbreak, leading causes of death in the US during the COVID-19 pandemic, antibody evasion by subvariants, broadly-neutralizing antibodies against emerging variants, factors associated with severe outcomes among hospitalized immunocompromised adults, measurement of the burden of hospitalizations during the pandemic, parental vaccine hesitancy in diverse communities, evaluating saliva sampling to improve access to diagnosis in low-resource settings, oral sabizabulin for high-risk hospitalized adults, lower-risk of multisystem inflammatory syndrome in children, and neurovascular injury with complement activation and inflammation during infection.

TWiV 914: COVID-19 clinical update #121 with Dr. Daniel Griffin

In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin

In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms …

TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin Read More »

Scroll to Top